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Dear Editor,
Pituitary adenomas (PAs) are one of the most common 
intracranial tumors, which can result in significant mor-
bidity and can cause mortality either by exerting central 
pressure effects from the pituitary mass or by secreting 
excessive pituitary hormones [1]. Depending on their ca-
pability to produce hormones, PAs are classified as clin-
ically functioning and nonfunctioning (NF). Functioning 
PAs include 6 subtypes,  characterized by hypersecretion 
of prolactin (PRL), growth hormone (GH), adrenocorti-
cotropin (ACTH), gonadotropins including follicle stimu-
lating hormone and luteinizing hormone (GT), thyrotropin 
(TSH) or multiple hormones (plurihormonal), respectively. 
We and other group recently reported the recurrent ge-
netic mutations in ACTH-PAs [2, 3]. Previous studies 
also identified genetic alterations in GH-PAs by whole-
genome and -exome sequencing [4, 5] and in 7 NF-PAs 
by exome analysis [6]. Due to challenges in collection 
and preparation of PA samples, exome-wide sequencing 
of other subtypes, including the PRL-, GT-, TSH-, and 
plurihormonal PA subtypes, has not been reported yet.
To provide a comprehensive genetic landscape of all 
7 subtypes of PAs, we examined the somatic mutational 
landscape of 125 PAs, including 20 NF-PAs, 20 PRL-
PAs, 20 GH-PAs, 20 ACTH-PAs, 20 GT-PAs, 10 TSH-
PAs, and 15 plurihormonal PAs. Plurihormonal PAs in 
this series secreted GH+PRL (n = 11), GH+ACTH (n 
= 2), or GH+TSH (n = 2). The analysis of 20 ACTH-
PAs included 12 tumor samples analyzed in our previous 
study [2]. The clinical characteristics of these patients are 
summarized in Supplementary information, Table S1A. 
The detailed methods are described in Supplementary 
information, Data S1 and Figure S1A. We identified 412 
somatic mutations in 125 PAs (Supplementary informa-
tion, Table S1B). This analysis confirmed a relatively 
low number of somatic mutations per tumor across all 7 
PA subtypes (mean = 3.3 mutations per exome; Figure 
1A) [3-6]. The predominant substitution was C>T/G>A 
transitions which accounted for 41% of all substitutions 
across all PA subtypes, followed by T>C/A>G transitions 
(23%), similar to other intracranial tumors (Supplemen-
tary information, Figure S1B).
Recurrently-mutated genes are shown in Figure 1A. 
We confirmed mutations in G protein subunit α (GNAS), 
ubiquitin-specific protease 8 (USP8), Nuclear Receptor 
Subfamily 3 Group C Member 1 (NR3C1), and Menin 1 
(MEN1) in PAs and identified new somatic variants in 
these genes. Activating mutations of GNAS have long 
been known to play a role in pathogenesis of GH-PAs [7].
In this study, GNAS mutations were identified in 54% of 
all GH-secreting tumors, including 8 of 20 GH-monose-
creting tumors and 11 of 15 plurihormonal tumors that 
secreted GH and another hormone. The high frequency of 
GNAS mutations in GH-PAs is consistent with previous 
findings [4]. GNAS alterations included p.R201C (n = 
14), p.R201H (n = 1), p.Q227L (n = 3) and a novel p.G49R 
(n = 1) mutation. USP8 is a deubiquitinating enzyme that 
protects growth factor receptors including EGFR from 
degradation. Highly frequent USP8 mutations in ACTH-
PAs have been shown by our group and others [2, 3]. In 
this study, USP8 mutations were identified in 11 out of 
20 ACTH-PAs, among which all mutation types have 
been described previously [2, 3]. We also identified novel 
truncation mutations in the glucocorticoid receptor gene 
NR3C1 in two ACTH-PAs that did not contain USP8 mu-
tations: p.Q632X-p.S512fs and p.R714P-p.630_630del. 
This is consistent with previous findings implicating 
mutations targeting NR3C1 as an uncommon contributor 
to ACTH-PA pathogenesis [2]. We additionally identified 
two novel somatic loss-of-function mutations in MEN1, 
including c.208_214del:p.D70fs and c.G608A:p.W203X, 
both in plurihormonal PAs producing GH and PRL from 
patients without a history of familial MEN syndrome 
and without germline MEN1 mutations. While germline 
MEN1 mutations have long been linked to PAs, MEN1 
mutations have also been reported as rare somatic events 
in sporadic PAs [8].
We also identified recurrently-mutated kinesin heavy 
chain isoform 5A (KIF5A) and growth factor recep-
tor-bound protein 10 (GRB10) as novel targets in two PA 
patients, respectively. KIF5A is a member of the kinesin 
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family of proteins, which participates in a multisubunit 
complex to promote intracellular organelle transport. So-
matic KIF5A mutations are found in prostate cancer [9], 
but had not been linked to PAs. We identified somatic 
mutations targeting the stalk (p.Y749C) and tail (p.T938I) 
domains of KIF5A in two PAs. GRB10 encodes an in-
tracellular adapter protein which interacts with several 
receptor tyrosine kinases and downstream signaling mol-
ecules to regulate secretion of insulin and other peptides 
[10]. We identified novel mutations in GRB10 including 
p.L357F and p.T155S, both in GH-PAs (2 out of 20 GH-
PAs, 10%), one of which also contained a GNAS muta-
tion, while the other one did not. GRB10 mutations in 
GH-PAs implicate GRB10 in the pathogenesis of GH-
PAs. In addition, mutations of other genes, such as IARS, 
SP100 and TRIP12, occurred in two cases (Figure 1A). 
We next focused on somatic copy number alternations 
(SCNA) in our panel of 125 PAs (Supplementary infor-
mation, Figure S1C). We found that 18% (22/125) of 
samples had SCNA involving < 10% of the genome; and 
32% (40/125) had considerably greater levels of genomic 
disruption, with > 80% of the genome involved. We ob-
served frequent loss of chromosomes 11q13.2 (q-value = 
1.01E-18) and 11p15.5 (q-value = 1.14E-16), consistent 
with the previous study [11]. We also observed loss of 
1p36.31 (q-value = 1.0098E-18), 9q34.11 (q-value = 
2.39E-18), 16p13.3 (q-value = 5.82E-18), and 3p21.31 
(q-value = 1.34E-17), and frequent gain of 20q13.33 
(q-value = 1.47E-29), 3p22.3 (q-value =  3.10E-22), 
1q31.3 (q-value = 5.06E-18), 7q21.11 (q-value = 1.54E-
17), and 16q12.2 (q-value = 2.59E-21). Our copy number 
data revealed frequent gains in regions encoding cohesin 
complex genes including synaptonemal complex genes 
SYCP1 on 1p13.2 and SYCP2 on 20q13.33 and RAD21 
cohesin complex like 1 (RAD21L1) gene on 20p13 (Fig-
ure 1A and Supplementary information, Figure S1C).
The identification of frequent amplifications in cohesin 
complex genes implicates cohesin deregulation in PA 
pathogenesis [12]. We found no significant association 
between SCNA as well as gains of cohesin complex re-
gions and clinical features and PA subtypes.
To determine whether any molecular pathways are 
preferentially targeted by mutations in different PA sub-
types, we performed gene set enrichment analysis using 
annotation based on the KEGG database (P < 0.05). NF-, 
GH-, PRL-, plurihormonal and ACTH-PAs were enriched 
for somatic mutations in overlapping molecular path-
ways such as Raf/MEK/ERK, PI3K/AKT/mTOR, cG-
MP-PKG, oxytocin, insulin and cAMP signalings (Figure 
1B). Interconnection based on pathway analysis between 
each subtype also suggested that GH-, PRL-, plurihor-
monal and ACTH-PAs are closely related with each other 
(Figure 1C). On the other hand, TSH- and GT-PAs were 
enriched for somatic mutations in a distinct set of molec-
ular pathways. In contrast to the other pituitary-secreted 
hormones which are polypeptides, TSH and GT are gly-
coproteins which share an identical α subunit. Moreover, 
TSH- and GT-secreting pituitary cells are both depen-
dent on the transcription factor GATA binding protein 2 
(GATA-2) during differentiation, while ACTH-, GH- and 
PRL-secreting cells are GATA-2 independent [13]. Our 
pathway analysis raises the possibility that TSH- and GT-
PAs may share features of their molecular pathogenesis.
Medical treatment for PAs is limited and patients fre-
quently require lifelong treatment. Genomic alterations 
identified in targetable genes may be useful to identify 
PA patients who could potentially benefit from targeted 
treatment in future clinical trials. For example, USP8 
mutation, by activating EGFR-MAPK signaling, ac-
counts for about 50% of ACTH-PAs [2, 3]. This provides 
Figure 1 (A) Somatic mutational and SCNA landscape of PAs. Tumor subtypes based on hormone secretion profile, patient 
age and gender, mutations in recurrently-mutated genes, number of mutations in each tumor subtype and relative number of 
different single-nucleotide substitutions in each tumor subtype are shown for 125 PAs. Copy number gain of SYCP1, SYCP2, 
and RAD21L1, as well as overall percentage of the genome disrupted by copy number variations, are all shown based on 
GISTIC analysis. (B) Significantly enriched pathways in each subtype based on pathway enrichment analysis. Bipartite net-
work of the association between subtypes and pathways, where a yellow node represents a subtype, a pink node represents 
a pathway, and the line between these two types of nodes indicates that the pathway was significantly (P < 0.05) associated 
with the subtype. Blue lines illustrate associations between a PA subtype and a molecular pathway based on our data in 
combination with previous whole-exome sequence data. The green lines show the associations between PA subtypes and 
well-known pathways based on prior publications. (C) Interconnections between each subtype based on pathway analysis. 
Each pair of subtypes is linked by a line with width corresponding to the number of pathways (containing at least two mu-
tated genes) shared by both subtypes. Node size reflects the number of pathways shared by any other subtypes. (D) The 
landscape of potential drug targets in 125 PAs. Genes encoding potential drug targets in seven altered pathways are shown. 
Genes mutated in PAs in this study are shown in ovals. Genes in blue ovals indicate cancer-related genes. Gene names in 
brown indicate potential drug targets, with their FDA-approved drugs shown in adjacent brown boxes. Orange stars indicate 
that drugs tested in phases I-III clinical trials are available to target the gene.
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a rationale for an effective treatment for patients with 
USP8-mutated ACTH-PAs by inhibiting USP8 catalytic 
activity or by anti-EGFR therapy, although anti-EGFR 
therapy has been shown to be promising in vitro and in 
animal models of ACTH-PAs in general [14]. We further 
sought to determine whether any potentially actionable 
cellular pathways are disrupted by mutations in PAs. 
We found 7 pathways enriched for cancer-related genes 
that were mutated in our series of 125 PAs (Figure 1D): 
cAMP signaling, cell cycle, PI3K-Akt signaling, immune 
response signaling, MAPK signaling, endocrine signal-
ing and Rap1 signaling pathways. We next analyzed 48 
existing drugs which target a critical molecule in one of 
these 7 pathways. Among those 48 drugs, 21 drugs are 
FDA-approved and 27 drugs are in phases I-III clinical 
trials. Genes encoding drug targets inthese pathways in-
cluded FGF4, GNAS, HDAC4, NFkB1, NOS3 and SYK 
(Supplementary information, Table S1C). Altogether, 
28% of PA patients in this series had tumors with a mu-
tation in a potentially actionable gene in one of these 7 
pathways. This analysis suggests that using drugs to di-
rectly target the disrupted pathways may not be a straight 
forward approach in PAs, as potentially actionable path-
ways disrupted by somatic mutations were heterogeneous 
among PAs and were only found in a minority of tumors.
We then attempted to identify links between our muta-
tional data and the clinical characteristics of PA patients. 
We retrospectively collected clinical information of these 
patients, including age, tumor size, clinical presentation, 
and invasion for our entire set of 125 PAs (Supplemen-
tary information, Table S1A). Invasiveness is one of the 
most important clinical phenotypes of PAs. Invasive PAs 
are always life threatening due to severe symptoms, high 
mortality and morbidity after surgery, and high incidence 
of post-operative recurrence. In our cohort, 157 muta-
tions were detected in the invasive tumor group and 222 
mutations were in the non-invasive group. As a whole, 
no significant difference was observed in the number 
of mutations or the number of targetable mutations or 
pathways between the invasive and non-invasive tumors.
In GH-PAs, GNAS mutation has been linked to tumor 
invasion and drug resistance to somatostatin analogs 
such as octreotide in several studies but not others [15]. 
In our cohort, GNAS mutation was inversely correlated 
with tumor invasiveness as determined by pathologic 
analysis, in which 40% of the GNAS-mutated tumors 
showed invasion compared to 60% of the GNAS-WT 
tumors with invasion (P = 0.036). Also, GNAS mutation 
was associated with drug resistance, with 15.4% of the 
GNAS-mutated tumors showing resistance versus 84.6% 
of the GNAS-WT tumors showing resistance (P = 0.001). 
We also confirmed that ACTH-PAs with mutated USP8 
were significantly smaller in size than those with wild-
type USP8 (mean = 1.0 vs 1.9 cm in maximum dimen-
sion, P < 0.001) [2]. No other significant associations 
were observed between mutations and basic clinical data, 
either among the group of all PAs or among any PA sub-
types.
In summary, we for the first time present a currently 
largest genome-wide mutational and SCNA landscape 
of PAs and a comprehensive genetic landscape for all 7 
PA subtypes. We confirmed GNAS mutations in GH-PAs, 
USP8 mutations in ACTH-PAs, and revealed new so-
matic variants of GNAS, MEN1 and NR3C1. Further, we 
identified KIF5A and GRB10 as novel recurrently-mutat-
ed genes in PAs. Molecular pathways related to specific 
pituitary hormones were differentially targeted by ge-
netic alterations in the various PA subtypes, and a subset 
of tumors contained genetic alterations in pathways that 
may be amenable to therapeutic interventions. This study 
provides insights into PA pathogenesis and may allow 
for the design of functional studies that further delin-
eate the biologic basis of the various PA subtypes. We 
estimated that exome sequencing of 20 samples would 
identify genes mutated at 30% frequency among a single 
subtype. Further studies with much larger sample sizes 
will be needed to identify driver mutations occurring at 
a lower frequency in these subtypes. Future studies will 
also be needed to identify whether miRNAs, noncoding 
regions, or methylation-related events may contribute to 
the pathogenesis of PAs.
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